Asthma Reporting with Anti-TNFα Drugs used in Inflammatory Joint Diseases: A Vigibase® Study with Disproportionality Analysis

Lung. 2026 Mar 27;204(1):19. doi: 10.1007/s00408-026-00883-1.

Abstract

Large studies investigating asthma as a potential adverse event of anti-TNFα drugs are lacking. In our study, asthma was more likely to be reported with anti-TNFα drugs compared to biologics and small molecules in RA but exclusively with adalimumab.

Keywords: Adverse event; Anti-TNFα drugs; Asthma; Rheumatic diseases.

MeSH terms

  • Adalimumab / adverse effects
  • Adult
  • Adverse Drug Reaction Reporting Systems
  • Aged
  • Antirheumatic Agents* / adverse effects
  • Arthritis, Rheumatoid* / drug therapy
  • Asthma* / chemically induced
  • Asthma* / epidemiology
  • Biological Products* / adverse effects
  • Female
  • Humans
  • Male
  • Middle Aged
  • Tumor Necrosis Factor-alpha* / antagonists & inhibitors

Substances

  • Tumor Necrosis Factor-alpha
  • Adalimumab
  • Antirheumatic Agents
  • Biological Products